Republicans query stakeholders on drug discount program

"With the reliance on self-policing among participating manufacturers and covered entities and the increase in the number of new settings in which the program is offered, the risk of improper purchases or diversion of 340B drugs has significantly increased," the members write. "The problems identified by the GAO as it relates to the oversight responsibilities of each party and the expansion of the program need resolution."

The letters are signed by Rep. Joe Pitts (R-Pa.), chairman of the House Energy and Commerce Health subcommittee, and by Sens. Chuck Grassley (R-Iowa), Michael Enzi (R-Wyo.) and Orrin Hatch (R-Utah.).

More in Regulation

FDA issues guidance for reusable medical devices linked to 'superbugs'

Read more »